Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BECTON DICKINSON & COBDX · Entity 2498 | Director | January 28, 2025 | January 30, 2025 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | August 05, 2022 | August 08, 2022 |
| Orthofix Medical Inc.OFIX · Entity 1975 | Director | April 08, 2024 | April 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BECTON DICKINSON & CO
Report date January 28, 2025 · Filed January 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,264 |
Reported balance
After 2025-01-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-28 · Grant · Acquired 930 · Balance 14,264 F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.
F2: Includes units acquired through dividend reinvestment since the last report filed by the reporting person.
HAEMONETICS CORP
Report date August 05, 2022 · Filed August 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,545 |
Reported balance
After 2022-08-05 transaction · row 1
1 source rowRow 1 · 2022-08-05 · Grant · Acquired 2,730 · Balance 19,545 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Orthofix Medical Inc.
Report date April 08, 2024 · Filed April 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,803 |
Reported balance
After 2024-04-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-04-08 · Tax withholding · Disposed 47,486 · Balance 112,803 F1: Includes 32,763 previously reported deferred stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 32,763 previously reported deferred stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2025 Filed Jan 30, 2025 21:05 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001305 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,264 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 20:54 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | Tax withholdingCommon Stock | 47,486 | $14.23 | $675,725.78 |
DisclosureSEC source: 0000950170-24-043032 · ownership.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,803 F1 · balance_after: Includes 32,763 previously reported deferred stock units. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:11 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001295 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,242 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| October 15, 2023 Filed Oct 17, 2023 21:14 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 120,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052978 · doc4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,625 F1 · shares: The restricted stock units vest in full ninety (90) calendar days following the date that a successor Chief Executive Officer of Issuer assumes office following the Reporting Person's discontinuation of service as Interim Chief Executive Officer of Issuer. F2 · balance_after: Includes 32,763 previously reported deferred stock units. Read SEC document |
| June 19, 2023 Filed Jun 21, 2023 20:18 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 3,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038789 · doc4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,949 F1 · price: Represents an award of deferred stock units that vest in full on the earlier of (i) June 30, 2024 or (ii) the date on which the issuer holds its 2024 annual meeting of stockholders, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 32,763 deferred stock units. F3 · balance_after: Includes 1,304 shares purchased by the reporting person, on April 30, 2023, under the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c). Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 23:02 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 848 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001429 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,425 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:52 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002645 · doc4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,754 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the first anniversary of the grant date, January 5, 2023. F2 · balance_after: Includes 28,872 deferred stock units. Read SEC document |
| January 05, 2023 Filed Feb 9, 2023 23:07 UTC Amendment | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008138 · doc4a.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,056 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders. F2 · shares: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023. F3 · balance_after: Includes 29,174 deferred stock units. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020696 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,545 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:35 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 8,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035049 · doc4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,443 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vest in full on the first anniversary of the grant date, June 6, 2022. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 13:37 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-001643 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,499 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 21:04 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | PurchaseCommon Stock | 1,660 | $30.27 | $50,248.20 |
DisclosureSEC source: 0001209191-21-065776 · doc4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,947 Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023391 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,815 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:45 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantStock Option (right to buy) · Derivative | 21,361 | $0.00 Strike: $40.58 | $0.00 |
DisclosureSEC source: 0001209191-21-042755 · doc4.xml · derivative · entry 2 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,361 Underlying: Common Stock · 21,361 shares Expires 2031-06-21 F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, June 21, 2021. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:45 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 5,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042755 · doc4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,976 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 13:46 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-21-000005 · edgar.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,661 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:15 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021975 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,738 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 13:23 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 765 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-20-000012 · edgar.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,832 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025263 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,755 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| April 17, 2019 Filed May 30, 2019 17:12 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | SaleCommon Stock | 45 | $223.04 | $10,036.80 |
DisclosureSEC source: 0001543407-19-000032 · edgar.xml · nonDerivative · entry 4 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,007 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 16, 2019 Filed May 30, 2019 17:12 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | PurchaseCommon Stock | 30 | $247.96 | $7,438.80 |
DisclosureSEC source: 0001543407-19-000032 · edgar.xml · nonDerivative · entry 3 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,052 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 15:40 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000008 · edgar.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,692 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 22, 2019 Filed Jan 25, 2024 21:08 UTC Amendment | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001292 · form4a.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,324 F1 · balance_after: This Form 4 is being amended to reflect the proper number of shares owned by the reporting person which incorrectly included shares previously gifted. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024055 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,295 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 22, 2018 Filed May 30, 2019 17:12 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | PurchaseCommon Stock | 45 | $239.01 | $10,755.45 |
DisclosureSEC source: 0001543407-19-000032 · edgar.xml · nonDerivative · entry 2 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,022 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| April 13, 2018 Filed May 30, 2019 17:12 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | PurchaseCommon Stock | 285 | $225.89 | $64,378.65 |
DisclosureSEC source: 0001543407-19-000032 · edgar.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,977 F1 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 17:13 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 941 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-18-000021 · edgar.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,259 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 22:21 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,329 | $39.27 | $169,999.83 |
DisclosureSEC source: 0001127602-17-024409 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,599 F1 · shares: Restricted Stock Unit grant which vests 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 18:55 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-17-000003 · edgar.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,318 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| October 25, 2016 Filed Oct 28, 2016 00:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,969 | $34.21 | $169,989.49 |
DisclosureSEC source: 0001127602-16-065437 · form4.xml · nonDerivative · entry 1 BURZIK CATHERINE M · CIK 0001261141 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,969 F1 · shares: Restricted Stock Unit Grant which vest 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.